TET2 converts 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) in DNA and is frequently mutated in myeloid malignancies, including myeloproliferative neoplasms (MPN).
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Introduction
Tet1, Tet2, and Tet3 convert 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) in DNA from various mouse tissues 1-3 . Acquired mutations in TET2 have been found in a variety of myeloid malignancies including myeloproliferative neoplasms (MPN) 4-8 . These defects are considered to be loss of function mutations affecting a hematopoietic stem cell, but their actual involvement in malignant hematopoiesis remains unclear. TET2 mutations have been recently associated with impaired hydroxylation of 5-mC in myeloid cancers, and Tet2 has been shown to regulate murine myeloid differentiation 9, 10 . As in mice, TET2 expression is predominant in hematopoietic cells in humans 5 . To test whether TET2 alterations could have consequences in 5-mC hydroxylation and in the biology of human hematopoietic cells, we studied primary cells from MPN patients with or without TET2 mutations, as well as cell lines and normal CD34 + cells where TET2 expression was knocked down by RNA interference.
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Study design

Patient samples
The study was approved by the Local Research Ethics Committee of Assistance Publique Hôpitaux de Paris. Peripheral blood was collected from 58 MPN patients (Table S2 ) and 31 healthy individuals with their informed consent, in accordance with the Declaration of Helsinki. Umbilical cord blood samples were collected from healthy newborns with mothers' consent. CD34 + cells or granulocytes were isolated as described 11 .
Nucleic acid extraction
DNA and RNA were extracted using Qiagen kits (Qiagen).
Quantification of 5-hmC
Cytosine, 5-mC, and 5-hmC were quantified using high performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) 12, 13 (Figure S1) . Dot blots were obtained by spotting DNA onto nylon hybond N+ membranes (Amersham). Membranes were washed, air-dried, U.V. cross-linked, blocked and incubated with anti-5-hmC antibody (Active Motif) (1:10,000) and horseradish peroxidase-conjugated anti-rabbit IgG second dary antibody (Jackson Immunoresearch). To control spotting, blots were stained with 0.02% methylene blue in 0.3M sodium acetate (pH5.2). Immunofluorescent staining was performed using anti-5-hmC antibody and Alexa-546 conjugated secondary antibody (Molecular Probes). Nuclei were stained with Hoechst 33342 (Molecular Probes) and cells were examined using a LSM 510 microscope (Zeiss).
Real time quantitative RT-PCR
PCR were performed using primers and probes listed in table S1 with an ABI Prism GeneAmp 7500 (Applied Biosystems).
TET2 knockdown by lentiviral delivery of short hairpin RNA (shRNA)
MO7e, Kasumi-1, TF1, UKE1, HL60, ant UT7 cell lines or CD34 + cells were transduced as previously described 14 with lentiviruses expressing the green fluorescent protein (GFP) and
For personal use only. on April 19, 2017. by guest www.bloodjournal.org From either shRNA-TET2 (5'-GGGTAAGCCAAGAAAGAAA-3') or shRNA-scramble (5'-GCCGGCAGCTAGCGACGCCAT-3') as control. GFP-positive cells were sorted using a MOFLO (Beckman Coulter) cell sorter. TET2 protein knockdown was assessed by western blot using an anti-TET2 antibody generated in the mouse and an anti-HSC70 antibody (Enzo Life Sciences).
Cell cultures and flow cytometry
CD34 + cells were grown in colony forming cell (CFC) assays in methylcellulose 11 or in liquid cultures stimulating erythroid, granulo-monocytic, or monocyte/macrophage differentiation using SCF (Immunex, 50 ng/mL), IL-3 (Novartis, 100 IU/mL), EPO (Bellon, 3 IU/mL), FLT3-L 
Results and discussions
We first assessed whether TET2 mutations could influence 5-hmC levels in MPN. CD34 + cells from two healthy individuals, two mutant TET2 patients and one wild-type TET2 patient were grown in erythroid differentiation culture to obtain sufficient DNA for HPLC-MS/MS experiments. On day 8, 5-mC levels were similar but the ratio of 5-hmC to 5-mC was lower in DNA from mutant TET2 cells than in wild-type TET2 and control cells (Figure S1). We next analyzed peripheral blood leukocytes from a series of 19 healthy controls, 19 wild-type TET2 patients, and 15 mutant TET2 patients with an HPLC-MS/MS technique allowing the use of smaller amounts of DNA ( Figure S1) . A trend toward lower 5-hmC values was seen in the For personal use only. on April 19, 2017. by guest www.bloodjournal.org From group of mutant TET2 patients (median=0.495) when compared to healthy control values (median=0.838, P=0.0686, Mann-Whitney 2-tailed test). We then analyzed the 5-hmC content in purified granulocytes from an additional series of samples from 10 healthy controls, 14 wild-type TET2 patients, and 9 mutant TET2 patients using dot blots with anti-5-hmC antibody. Analysis of 5-hmC spot intensities relative to methylene blue signals revealed that mutant TET2 MPN granulocytes had a reduction in 5-hmC content compared to granulocytes from both controls and wild-type TET2 MPN patients with a median normalized value of 0.526 versus 0.986 and 0.819, respectively, (P<0.05, Mann-Whitney 2-tailed test) ( Figure 1A, B) . These results show that some MPN patients have an impaired hydroxylation of 5-mC, especially when they carry a TET2 mutation. However some wild-type TET2 patients had also low 5-hmC levels, as reported in other myeloid malignancies 10 , and a few individuals had high 5-hmC contents. Known mutations, such as IDH1/2 mutations, 9 or unknown alternative genetic lesions affecting TET2 function or DNA hydroxy-methylation may be responsible for these variations in 5-hmC content.
To confirm that 5-hmC levels were directly dependent on TET2 function in human hematopoietic cells we used lentiviral delivery of shRNA-TET2 or control shRNA-scramble in leukemic cell lines. Quantitative RT-PCR and western blot analyses showed efficient TET2 knockdown by shRNA-TET2 ( Figure 1C , D, S2). In MO7e cells HPLC-MS/MS revealed that TET2 knockdown led to a dramatic reduction of the 5-hmC/5-mC ratio (0.55‰ versus 2.02‰ in control cells, P=0.005, unpaired Student t test) ( Figure 1E, Figure S3 ). Decreased 5-hmC levels were also observed in shRNA-TET2-expressing TF1, Kasumi-1, UKE1, MO7e, UT7, and HL60 cells using 5-hmC dot blots (Figure 1F, S3) . These data indicate that TET2 knockdown results in decreased 5-hmC levels in human leukemic cell lines, thus arguing for the role of the protein in generating 5-hmC in human hematopoietic cells.
As TET2 mutations are found in myeloid malignancies, we hypothesized that the disruption of TET2 function may disturb myelopoiesis. Thus we transduced CD34 + cells from umbilical cord blood with shRNA-TET2 and shRNA-scramble lentiviruses. Transduced cells were analyzed in long-term B/NK/GM culture, CFC assays, and liquid cultures for granulo-For personal use only. on April 19, 2017. by guest www.bloodjournal.org From monocytic or erythroid differentiation. We assessed efficient TET2 knockdown by analyzing both TET2 expression and 5-hmC levels (Figure S4 and 2A) . In B/NK/GM conditions, TET2knockdown CD34 + CD38cells gave rise to 52.4±4.3% of myeloid clones versus 35.5±3.1% for control cells (P=0.003, unpaired Student t test) ( Figure 2B) . CFC assays showed that TET2 knockdown had no impact on the total number of colonies. However granulo-monocytic colonies were slightly increased in number and size whilst erythroid colonies were decreased (Figure 2C,D) . These results suggest that the granulo-monocytic compartment was advantaged at the expense of erythroid differentiation. Impaired terminal erythroid differentiation was confirmed when analyzing CD36 and glycophorin-A acquisition of CD34 + cells grown in liquid erythroid differentiation culture for 14 days, with 57±8% of glycophorin-A/CD36-double-positive erythroblasts within shRNA-TET2 expressing cells as compared to 81±4% in control cells (P=0.024, unpaired Student t test) (Figure 2E, F) . In granulomonocytic liquid culture assay, morphologic analysis revealed that shRNA-TET2-expressing cells contained more monocytic and less granulocytic cells than control cells (47±4% versus 37±3%, and 52±4% versus 62±3%, respectively at day 10, P<0.05, unpaired Student t test) ( Figure S5 ). Immunophenotypic analyses confirmed this observation. On day 10 and 15, the percentages of granulocytic CD15 + cells were lower in TET2-knockdown cells (20±2 and 19±2%, respectively) compared to shRNA-scramble expressing cells (36±4 and 26±2%, respectively), while the percentages of monocytic CD14 + cells were higher in TET2knockdown cell suspension (52±1 and 53±2%, respectively) than in control culture (39±4 and 42±3%, respectively) (Figure 2G,H, and S6) . In contrast, cultures in the presence of M-CSF revealed no significant difference between shRNA-TET2-expressing cells and control cells ( Figure S7) . In these experiments we did not observe any increase in immature myeloid cells as recently reported with a Tet2 shRNA in the mouse 9 .
Altogether, our results confirm the ability of TET2 to convert 5-mC to 5-hmC in human hematopoietic progenitor cells and demonstrate that TET2 knockdown skews human progenitor differentiation toward the myeloid lineage, with an advantage for monocytic development at the expense of the granulocytic lineage. Moreover, we observed an For personal use only. on April 19, 2017. by guest www.bloodjournal.org From impairment of erythroid differentiation. These results could explain the high frequency of TET2 mutations in chronic myelomonocytic leukemia (CMML), a disease associated with both myelodysplastic features and an expansion of the monocytic compartment 6, 16, 17 . In addition other lesions such as JAK2V617F could behave as a rescue of myelopoiesis defects of TET2 mutant cells and lead to MPN 7, 18 or refractory anemia with ringed sideroblasts associated with marked thrombocytosis 19 .
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Figure legends
